PMID: 19557121Jun 27, 2009Paper

Update on the management of symptoms in schizophrenia: focus on amisulpride

Neuropsychiatric Disease and Treatment
Ann M Mortimer


Amisulpride is an atypical antipsychotic drug with a unique receptor pharmacology which is dose dependent. It is a standard treatment in dysthymia as well as in psychosis. Amisulpride is efficacious, effective and well tolerated in positive symptoms of schizophrenia: there is extensive evidence that it treats negative symptoms when given in low doses, although relative lack of EPS and an antidepressant effect may contribute. In first-episode patients amisulpride is an option, although there is little comparative work available. Amisulpride has the best evidence as an effective adjunct to clozapine treatment. Regarding intellectual function, amisulpride appears cognitive sparing but the clinical relevance of this remains obscure. There is evidence that amisulpride can improve social function but again there is little comparative work to demonstrate any particular advantages. Regarding the current conventional versus atypical antipsychotic controversy, amisulpride did better in switching studies and meta-analyses than in the single large pragmatic randomized trial reported to date. It is a versatile drug, and may offer advantages over other atypical antipsychotic drugs in the treatment of negative and depressive symptoms, and tol...Continue Reading


Jan 1, 1995·The British Journal of Psychiatry : the Journal of Mental Science·P BoyerF Aubin
Jan 1, 1997·The British Journal of Psychiatry : the Journal of Mental Science·H LooO Fleurot
Mar 31, 1998·The British Journal of Psychiatry : the Journal of Mental Science·J C SpellerJ L Alberts
Jan 23, 1999·Biological Psychiatry·G GründerO Benkert
Apr 11, 2000·Journal of Psychopharmacology·M Papp, J Wieronska
Oct 14, 2000·European Psychiatry : the Journal of the Association of European Psychiatrists·P CarrièreT Lempérière
Jan 24, 2002·The Journal of International Medical Research·T Burns, R Bale
Feb 2, 2002·The American Journal of Psychiatry·Stefan LeuchtWerner Kissling
Mar 13, 2002·CNS Drugs·Monique P Curran, Caroline M Perry
Jul 20, 2002·Journal of Affective Disorders·Paola RoccaFilippo Bogetto
Aug 31, 2002·Current Medical Research and Opinion·T BurnsK Demyttenaere
Apr 16, 2003·Schizophrenia Bulletin·Jitschak G StorosumAndré W Broekmans
Jun 11, 2003·Archives of General Psychiatry·John M DavisIra D Glick
Aug 2, 2003·The International Journal of Neuropsychopharmacology·Muriel CanalCatherine Coulouvrat
Dec 4, 2003·Progress in Neuro-psychopharmacology & Biological Psychiatry·Hans-Jürgen Möller
Feb 19, 2004·European Psychiatry : the Journal of the Association of European Psychiatrists·Mathias ZinkJohannes Thome
Feb 20, 2004·The International Journal of Neuropsychopharmacology·Ann M Mortimer
Jun 19, 2004·The International Journal of Neuroscience·Philip J TysonAnn M Mortimer
Feb 18, 2005·Australasian Psychiatry : Bulletin of Royal Australian and New Zealand College of Psychiatrists·Brian Cook, Gerry Hoogenboom
Mar 23, 2005·Der Nervenarzt·M Zink, H Dressing
May 4, 2005·Progress in Neuro-psychopharmacology & Biological Psychiatry·Simon SurguladzeMichael J Travis
Dec 1, 2005·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·R Zanardi, E Smeraldi
Jan 18, 2006·European Psychiatry : the Journal of the Association of European Psychiatrists·Josep Maria HaroPeter B Jones
Mar 15, 2006·European Psychiatry : the Journal of the Association of European Psychiatrists·V P KontaxakisC R Soldatos
Oct 27, 2006·Human Psychopharmacology·Brendan P MurphyPatrick D McGorry
Nov 10, 2006·Journal of Psychopharmacology·Jenifer Chan, Melinda Sweeting
Nov 23, 2006·European Psychiatry : the Journal of the Association of European Psychiatrists·J-M Vanelle, S Douki
Mar 1, 2007·Pharmacopsychiatry·A HoferW W Fleischhacker
Aug 11, 2007·Human Psychopharmacology·Ann M MortimerUNKNOWN SOLIANOL Study Group
Oct 11, 2007·Molecular Psychiatry·G KaroutzouD E Dietrich
Mar 4, 2008·The British Journal of Psychiatry : the Journal of Mental Science·Shôn Lewis, Jeffrey Lieberman

❮ Previous
Next ❯


Dec 31, 2009·European Archives of Psychiatry and Clinical Neuroscience·André Quincozes-SantosCarmem Gottfried
Jun 6, 2012·Clinical Rheumatology·Fernando Rico-VillademorosElena P Calandre
May 1, 2013·Clinical Psychology Review·Emily EisnerChristine Barrowclough
May 17, 2013·Schizophrenia Research·Michael C DavisStephen R Marder
Nov 21, 2013·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Michael C DavisStephen R Marder
Aug 14, 2015·American Journal of Therapeutics·Manu AroraVivek Mahajan
Dec 1, 2011·Therapeutic Advances in Psychopharmacology·Zeynep KotanSelçuk Kirli
Aug 5, 2017·Drugs·Selene R T VeermanLieuwe de Haan
Mar 13, 2014·Archives of Pharmacal Research·Keumhan NohWonku Kang

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here

Related Papers

Current Medical Research and Opinion
B Green
Journal of Neuroimmune Pharmacology : the Official Journal of the Society on NeuroImmune Pharmacology
Kathleen M GrantRick A Bevins
© 2021 Meta ULC. All rights reserved